Benztropine Mesylate Injection
- Packing: 2 Ml Ampoule.
- Available Strength : 1 Mg/Ml
Description
Product Description: Benztropine Mesylate Injection is a sterile solution containing benztropine mesylate, a medication used for the treatment of Parkinson's disease and extrapyramidal symptoms induced by antipsychotic medications. Benztropine mesylate is an anticholinergic agent that works by blocking the action of acetylcholine in the central nervous system, thereby alleviating symptoms associated with dopamine imbalance.
Indications and Usage: Benztropine Mesylate Injection is indicated for the treatment of Parkinson's disease and drug-induced extrapyramidal symptoms, including dystonia, dyskinesia, and akathisia. It is used as an adjunctive therapy in patients who do not respond adequately to other antiparkinsonian medications or as an alternative to oral formulations in patients who are unable to take medications orally.
Dosage and Administration: The dosage of Benztropine Mesylate Injection varies depending on the patient's age, weight, and medical condition, as well as the severity of symptoms. It is administered intramuscularly or intravenously. The recommended initial dose for adults is typically 1 to 2 mg injected slowly, with additional doses of 1 to 2 mg given every 30 to 60 minutes until the desired response is achieved. The maximum daily dose should not exceed 6 mg.
Dosage Forms and Strengths: Benztropine Mesylate Injection is available as a sterile solution in vials or ampules for parenteral administration. Each mL of solution contains 2 mg of benztropine mesylate. It is supplied in various packaging sizes to accommodate different clinical settings and patient needs.
Contraindications: Benztropine Mesylate Injection is contraindicated in patients with a known hypersensitivity to benztropine mesylate or any component of the formulation. It should not be used in patients with narrow-angle glaucoma, obstructive uropathy, or myasthenia gravis. Use caution in patients with prostatic hypertrophy, gastrointestinal obstruction, or urinary retention.
Warnings and Precautions: Use caution when administering Benztropine Mesylate Injection to elderly patients, as they may be more susceptible to anticholinergic effects, including confusion, constipation, and urinary retention. Monitor patients closely for signs of anticholinergic toxicity, particularly in the elderly and those with preexisting cognitive impairment. Use with caution in patients with a history of seizures or cardiovascular disease.
Adverse Reactions/Side Effects: Common adverse reactions associated with Benztropine Mesylate Injection include dry mouth, blurred vision, urinary retention, constipation, and tachycardia. Less common side effects may include confusion, hallucinations, and delirium. Severe adverse reactions, such as heatstroke, hyperthermia, or angioedema, are rare but may occur.
Drug Interactions: Benztropine Mesylate Injection may interact with other medications that have anticholinergic effects, such as tricyclic antidepressants, antihistamines, and antipsychotics. Concurrent use may potentiate anticholinergic toxicity and increase the risk of adverse reactions. Avoid concurrent use with other drugs that prolong the QT interval or induce torsades de pointes.
Use In Specific Populations Description: Safety and efficacy of Benztropine Mesylate Injection in pediatric patients, elderly patients, pregnant women, and nursing mothers have not been established conclusively. Use caution and individualize the dosage and administration based on the patient's age, weight, and medical condition.
How Supplied/Storage and Handling: Benztropine Mesylate Injection is supplied as a sterile solution in vials or ampules for parenteral administration. It should be stored at controlled room temperature (20°C to 25°C) away from light and moisture. Care should be taken to ensure proper storage and handling to maintain the integrity of the product. Unused portions should be discarded according to standard procedures for biohazardous waste.